Global Injectable Drugs Market 2017-2021

Overview of the global injectable drugs market

According to Technavio’s market research report, the global injectable drugs market will grow at a CAGR of more than 8% during the forecast period. The rising demand for self-injection devices is one of the key drivers that will be responsible for the market’s growth during the estimated period. The high demand for diabetes and other hormone replacement therapies is boosting the adoption of self-injection devices on a global level. Currently, the largest number of diabetes patients is witnessed in countries such as China, India, and the US. The lack of awareness and treatment facilities in the African region is responsible for the growing number of new diabetic cases. The adoption of self-injectable devices will continue to increase among the group of people that rely on a daily dose of insulin. This will positively influence the growth of the global injectable drugs market.

One of the key trends that will gain  traction in the market in the coming years is the entry of novel vaccines. The rising focus on the prevention and treatment of diseases such as cancer, hepatitis infection, HIV infection, and severe acute respiratory syndrome has resulted in the introduction of new therapeutic vaccines. Additionally, advancements of technology also led to the introduction of innovative vaccines such as dendritic cell vaccines, DNA vaccines, T-cell receptor peptide vaccines, and recombinant vector vaccines.

Competitive landscape and key vendors

The injectable drugs market is characterized by the presence of many companies. These vendors are increasingly competing against each other based on factors such as aggressive pricing, product efficacy, limited side effects, rich pipeline, and operational base. The advent of biosimilars, advancement in research activities, and the launch of novel therapies will strengthen the competitive environment of this marketspace.

Key vendors in this market are -

• AbbVie
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Sanofi

Other prominent vendors in the market include Bayer, Bristol-Myers Squibb, Merck, Takeda Pharmaceutical, and Teva Pharmaceutical.

Segmentation by molecule type and analysis of the injectable drugs market

• Biologics
• Small molecules

The rising inclination towards targeted therapies and personalized medicines is contributing to the high growth of biologics. Biologic products are used to treat diseases like cancer and autoimmune disorders such as Crohn’s disease and multiple sclerosis. The biologics segment will continue to gain popularity during the next few years due to the combination of biopharmaceutical production and advanced bioengineering.

Segmentation by geography and analysis of the injectable drugs market

• Americas
• APAC
• EME

The adoption of injectable medications in the US is driven by the increasing investments in the healthcare segment and the rising investment in research and developmental activities, especially in the oncology sector. The market will continue to grow in the Americas during the next few years due to the increasing prevalence rate of diseases such as cancer, autoimmune disorders, and hormonal disorders.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global injectable drugs market?
• What are the key market trends impacting the growth of the global injectable drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global injectable drugs market?
• What are the market opportunities and threats faced by the vendors in the global injectable drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global injectable drugs market?

Technavio also offers customization on reports based on specific client requirement